Targeted KRAS G12V degradation elicits efficient and durable lung adenocarcinoma regression in vivo [R_invivo_invitro]
RNA-seq (gene expression) · mouse · 23 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Samples
- 23 samples: 8 × T_R_InVivo_BL6 vs 6 × T_R_InVitro vs 6 × T_R_InVivo_NSG vs 3 × UT_InVitroGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE301620_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1285811 and SRA study SRP598061. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 23 samples.
How we read this: 4 replicated groups read from 23 sample titles; they account for 23 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9086583 UT_InVitro_1 UT_InVitro
- GSM9086584 UT_InVitro_2 UT_InVitro
- GSM9086585 UT_InVitro_3 UT_InVitro
- GSM9086586 T_R_InVitro_1 T_R_InVitro
- GSM9086587 T_R_InVitro_2 T_R_InVitro
- GSM9086588 T_R_InVitro_3 T_R_InVitro
- GSM9086589 T_R_InVitro_4 T_R_InVitro
- GSM9086590 T_R_InVitro_5 T_R_InVitro
- GSM9086591 T_R_InVitro_6 T_R_InVitro
- GSM9086592 T_R_InVivo_BL6_1 T_R_InVivo_BL6
- GSM9086593 T_R_InVivo_BL6_2 T_R_InVivo_BL6
- GSM9086594 T_R_InVivo_BL6_3 T_R_InVivo_BL6
- GSM9086595 T_R_InVivo_BL6_4 T_R_InVivo_BL6
- GSM9086596 T_R_InVivo_BL6_5 T_R_InVivo_BL6
- GSM9086597 T_R_InVivo_BL6_6 T_R_InVivo_BL6
- GSM9086598 T_R_InVivo_BL6_7 T_R_InVivo_BL6
- GSM9086599 T_R_InVivo_BL6_8 T_R_InVivo_BL6
- GSM9086600 T_R_InVivo_NSG_1 T_R_InVivo_NSG
- GSM9086601 T_R_InVivo_NSG_2 T_R_InVivo_NSG
- GSM9086602 T_R_InVivo_NSG_3 T_R_InVivo_NSG
- GSM9086603 T_R_InVivo_NSG_4 T_R_InVivo_NSG
- GSM9086604 T_R_InVivo_NSG_5 T_R_InVivo_NSG
- GSM9086605 T_R_InVivo_NSG_6 T_R_InVivo_NSG
- GSE301303 Targeted KRAS G12V degradation elicits efficient and durable lung adenocarcinoma regression in vivo 65 samples shares kras, g12v, adenocarcinoma, degradation, regression, efficient, targeted, elicits
- GSE301301 Targeted KRAS G12V degradation elicits efficient and durable lung adenocarcinoma regression in vivo [dTAG_expt1_RNAseq] 16 samples shares kras, g12v, adenocarcinoma, degradation, regression, efficient, targeted, elicits
- GSE269680 CDK8 remodels the tumor microenvironment to resist the therapeutic efficacy of targeted KRASG12D inhibition in pancreatic ductal adenocarcinoma (spatial) 15 samples shares kras, adenocarcinoma, targeted
- GSE252971 CasRx-Based KRASG12D Silencing for In Vivo Tumor Inhibition in Spontaneous Lung Adenocarcinoma 28 samples shares kras, adenocarcinoma
- GSE264527 Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with combined SOS1 and MEK Inhibition for Improved Immunotherapy Response 21 samples shares kras, adenocarcinoma
- GSE333534 Targeting KRAS in a TRP53/KRAS mouse and organoid model inhibits Barrett Esophagus to Gastroesophageal Adenocarcinoma progression 20 samples shares kras, adenocarcinoma
- GSE236258 Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation 15 samples shares kras, adenocarcinoma
- GSE235242 Senescent cancer-associated fibroblasts in pancreatic adenocarcinoma suppress CD8+ T cell activation and inhibit response to immune checkpoint therapy [Kras_p53] 14 samples shares kras, adenocarcinoma
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.